MX2015008757A - Controlled release formulations of lorazepam. - Google Patents

Controlled release formulations of lorazepam.

Info

Publication number
MX2015008757A
MX2015008757A MX2015008757A MX2015008757A MX2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A
Authority
MX
Mexico
Prior art keywords
release
lorazepam
controlled release
release formulations
dosing
Prior art date
Application number
MX2015008757A
Other languages
Spanish (es)
Inventor
Michael Vachon
Douglas A Saltel
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015008757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of MX2015008757A publication Critical patent/MX2015008757A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.
MX2015008757A 2013-01-09 2014-01-09 Controlled release formulations of lorazepam. MX2015008757A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (1)

Publication Number Publication Date
MX2015008757A true MX2015008757A (en) 2016-02-05

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008757A MX2015008757A (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam.

Country Status (16)

Country Link
EP (1) EP2943186A1 (en)
JP (1) JP2016504391A (en)
KR (1) KR20150127037A (en)
CN (1) CN105188682A (en)
AU (1) AU2014205356A1 (en)
BR (1) BR112015016322A8 (en)
CA (1) CA2897313A1 (en)
CL (1) CL2015001921A1 (en)
HK (1) HK1213803A1 (en)
IL (1) IL239778A0 (en)
MX (1) MX2015008757A (en)
PE (1) PE20151431A1 (en)
PH (1) PH12015501533A1 (en)
RU (1) RU2015128914A (en)
SG (1) SG11201505352RA (en)
WO (1) WO2014110248A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089330A1 (en) 2017-11-01 2019-05-09 Edgemont Pharmceuticals, Llc Trust Alcohol-resistant oral pharmaceutical compositions of lorazepam

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (en) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
KR850700212A (en) * 1984-03-21 1985-12-26 죠지 드모트 Sustained Release Pharmaceutical Wexel
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
JP2004513975A (en) 2000-12-05 2004-05-13 マクグレゴール　アレキサンダー Hydrostatic delivery system for controlled release of active substance
MXPA04000209A (en) 2001-07-10 2005-03-07 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery.
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (en) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Sublingual pharmaceutical composition based on a benzodiazepine central receptor agonist
KR100822519B1 (en) * 2005-02-15 2008-04-16 주식회사종근당 Gastric-retentive controlled release mono-matrix tablet

Also Published As

Publication number Publication date
AU2014205356A1 (en) 2015-07-30
BR112015016322A2 (en) 2017-07-11
KR20150127037A (en) 2015-11-16
CL2015001921A1 (en) 2015-12-18
IL239778A0 (en) 2015-08-31
HK1213803A1 (en) 2016-07-15
EP2943186A1 (en) 2015-11-18
RU2015128914A (en) 2017-02-14
JP2016504391A (en) 2016-02-12
CA2897313A1 (en) 2014-07-17
SG11201505352RA (en) 2015-08-28
CN105188682A (en) 2015-12-23
BR112015016322A8 (en) 2018-01-23
WO2014110248A1 (en) 2014-07-17
PE20151431A1 (en) 2015-09-23
PH12015501533A1 (en) 2015-10-05

Similar Documents

Publication Publication Date Title
HRP20181364T1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MY161022A (en) Dexmedetomidine premix formulation
IL271352B (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
MX2016011290A (en) Lipoic acid choline ester compositions and methods of use.
EP2925340B8 (en) Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
PH12015502556A1 (en) Modified release formulation
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
HK1222337A1 (en) Topical composition and carrier for administration of pharmaceutical or cosmetic active ingredients
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CY1123933T1 (en) LORAZEPAM EXTENDED RELEASE FORMULATIONS
MX2015016410A (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
PH12015501533A1 (en) Controlled release formulations of lorazepam
HK1204967A1 (en) Composition containing natural plant extracts as active ingredients, external skin preparation comprising the same, cosmetic preparation comprising the same and pharmaceutical preparation comprising the same
MX2015009077A (en) Fingolimod containing stable composition.
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
MX2015011101A (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters.
AR094391A1 (en) LORAZEPAM FORMULATIONS OF SUSTAINED RELEASE
MX2015011099A (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters.
UA99891C2 (en) Methyl-3-(3-r-6-imidazo[1,2-a]pyridine-2-yl)acrylate derivatives and process for the peparation thereof
IN2013MU03639A (en)
TH1401007652A (en) Aminotriazolopyridines for use in the treatment of inflammation and its pharmaceutical composition